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Abstract
Background: Tyro3, Axl, and Mertk (TAMs) are a family of three conserved receptor tyrosine kinases that have
pleiotropic roles in innate immunity and homeostasis and when overexpressed in cancer cells can drive
tumorigenesis.
Methods: In the present study, we engineered EGFR/TAM chimeric receptors (EGFR/Tyro3, EGFR/Axl, and EGF/
Mertk) with the goals to interrogate post-receptor functions of TAMs, and query whether TAMs have unique or
overlapping post-receptor activation profiles. Stable expression of EGFR/TAMs in EGFR-deficient CHO cells afforded
robust EGF inducible TAM receptor phosphorylation and activation of downstream signaling.
Results: Using a series of unbiased screening approaches, that include kinome-view analysis, phosphor-arrays,
RNAseq/GSEA analysis, as well as cell biological and in vivo readouts, we provide evidence that each TAM has
unique post-receptor signaling platforms and identify an intrinsic role for Axl that impinges on cell motility and
invasion compared to Tyro3 and Mertk.
Conclusion: These studies demonstrate that TAM show unique post-receptor signatures that impinge on distinct
gene expression profiles and tumorigenic outcomes.
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Background
Tyro3, Axl, and Mertk (abbreviated TAMs) are a family
of three homologous type I receptor tyrosine kinases
that have important roles in innate immunity and in the
oncogenic transformation of tumor cells [1–7]. Structur-
ally, TAMs share a conserved extracellular domain com-
prised of two tandem immunoglobulin-like (Ig) domains
and two tandem fibronectin type III (Fn-III) domains,
followed by a single trans-membrane spanning region
and an intracellular tyrosine kinase domain [2, 8–10].
The best-characterized ligands for TAMs are Growth
Arrest Specific Factor-6 (Gas6) and Protein S (Pros1)
that bind to the extracellular Ig domains of TAMs and
induce dimerization, tyrosine phosphorylation, and post-
receptor activation of downstream signaling pathways
[11–13]. Both Gas6 and Pros1 interact with externalized
phosphatidylserine (PS) on apoptotic cells [14–17] and
enveloped viruses [18–23] via their γ-carboxylated Gla
domain, thereby enabling TAMs to serve indirectly as
PS receptors for the clearance of apoptotic cells and for
viral entry.
While all three TAMs promote apoptotic cell clearance
and viral entry via the interactions with Gas6 and Pros1,
TAMs have different specificities and affinities towards
their ligands, exhibit different tissue expression patterns,
and their promoters are regulated by distinct extracellu-
lar stimuli [24, 25]. Axl, which is more prominently
expressed on bone-marrow derived dendritic cells
(BMDCs), is up-regulated under pro-inflammatory con-
ditions, and has high affinity for Gas6 (Kd in nM range)
but undetectable affinity for Pros1 [16, 26, 27]. On the
other hand, Mertk is more prominently expressed on
M2 macrophages, is induced under tolerogenic and anti-
inflammatory conditions and down-regulated by LPS,
binds both Gas6 and Pros1 with lower affinities (Kd in
uM range) [26, 28]. Tyro 3, which is the most widely
expressed and abundant member of the TAM family, is
highly expressed in the nervous system, also binds Gas6
and Pros1, although there appears to be preferential
specificity for Pros1 [25, 26, 29]. TAMs also display differ-
ent requirements for PS, whereby Mertk and Tyro3 can
be hyper-activated by their ligands in the presence of
PS-positive apoptotic cells or liposomes [16, 24, 25, 30].
However, despite such broad and dynamic expression pat-
terns that includes immune cell subsets of both myeloid
and lymphoid origin, vascular endothelial cells, epithelial
cells, cells of the reproductive tissues, neuronal cells, as
well as mesenchymal and neuronal stem cells [2, 3, 31],
TAMs are nonessential for embryogenesis, and single,
double or triple knockouts are viable without visible de-
velopmental and perinatal defects. However, during
post-pubescent aging, TAM knockouts display chronic
inflammation and autoimmune type disorders reminis-
cent of systemic lupus erythematosus (SLE) [31–34].
Collectively, in adults, TAMs have specialized homeo-
static functions that control the tolerogenic clearance
of apoptotic cells and the resolution and maintenance
of inflammation [24].
Adding complexity, TAMs also participate in a variety
of heterotypic interactions with specific cytokine
receptors, integrins, and cell adhesion molecules to pro-
foundly influence receptor versatility. For example, Axl
has been shown to participate in a heterotypic inter-
action with the Interferon type I receptor (IFNAR1) to
activate Stat1 and negatively regulate inflammatory
cytokine signaling via the expression of SOCS1 and
SOCS3 [4]. Mertk, on the other hand, functionally inter-
acts with αvβ5 integrin, to induce phagocytic uptake of
apoptotic cells and rod outer segments [35]. The inter-
face between TAMs, their ligands, and co-receptors
diversify the repertoire of signaling of this RTK family.
In addition to their complex regulation under physio-
logical conditions, all three TAMs are also strongly
implicated in human cancers, whereby aberrantly elevated
expression and signaling is often associated with cancer
progression, metastasis, and resistance to targeted therapies
[1–3, 36–38]. Indeed, many cancers, including cancers of
the breast, colon, glioblastomas, kidneys, leukemia’s, liver,
lung, melanomas, multiple myelomas, osteosarcomas, ovar-
ies, prostate, stomach, thyroid and uterine endometrium
display dys-regulated expression of one or more TAM
receptor tyrosine kinases [1–3]. From a therapeutic
standpoint, TAMs are interesting receptor targets in cancer
biology since their expression on innate myeloid cells in the
cancer microenvironment leads to immune subversion,
while their expression on tumor cells can drive oncogenic
transformation and survival.
Here we query a fundamental question in TAM biology
as to whether TAM specificity is achieved intrinsically at
the level of post-receptor activation of downstream signal-
ing. To address this issue, we developed reporter cell lines
to study TAM post-receptor signaling in a normalized
ligand-inducible system that eliminates differences in
ligand-specific TAM activation. While previous studies
have utilized various chimeric receptors, such as EGFR/
Tyro3 [13, 39], EGFR/Axl [40–42], EGFR/Mertk [43],
FMS/Mertk [44] and CD/Mertk [35, 45] to map early
post-receptor signals and demonstrate the fidelity of TAM
chimeric approaches, here we expressed EGFR-TAMs in
the EGFR negative CHO cells to systematically query
whether, upon ligand engagement, TAMs have overlap-
ping or unique post-receptor signaling signatures. By
interrogating post-receptor pathways using kinome-view,
phosphor-arrays, RNA-Seq and subsequent biological
validation, we show that TAMs activate unique intrinsic
post-receptor signaling pathways devoid of their differen-
tial reliance on endogenous ligands Gas6 and Pros1.
Moreover, these studies provide a rationale for the
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metastatic activity of Axl, whereby EGFR-Axl expressing
cells preferentially activate a tumorigenic signature that
promotes cytoskeletal reorganization, motility, invasion,
and in vivo, Axl knock-out in the triple negative breast
cancer cell line 4 T1 showed impaired tumor growth




Antibodies used were as follows: anti-hEGFR (Santa Cruz,
Sc-120), PE-Mouse anti- hEGFR (BD Biosciences, 555997),
anti-hTyro3 (Cell Signaling, D38C6), anti- phosphor-
hTyro3 (Aviva Systems Biology, OAAF00456), anti-hAxl
(Cell Signaling, C89E7), anti-phospho-Axl (Cell Signaling,
D12B2), anti-hMer (Cell Signaling, D21F11), anti-phospho-
Mer (FabGennix, PMKT-140AP), anti-phospho-STAT1
(BD Bioscience, 612233), anti-phospho-Akt (Ser473) (Cell
Signaling, 193H12), anti-phospho-Akt (Thr308) (Cell Sig-
naling, D25E6), anti-phospho-Erk1/2 (Cell Signaling,
20G11), anti-β-Actinin (Cell Signaling, MAB374), and anti-
phosphotyrosine pY99 (Millipore, 05–321), anti-hGas6
(R&D Systems, AF986), Human EGF (Invitrogen,
PHG0311). The secondary antibodies used for immunoblot
analysis were horseradish peroxidase–conjugated Affinipure
Goat anti-mouse (Jackson ImmunoResearch, 115-035-166)
and anti-rabbit (Jackson ImmunoResearch, 111-035-144).
Generation of chimeric receptor constructs and reporter
cell lines
The cDNA fragments encoding TAMs transmembrane
and intracellular domains were amplified by nested PCR
from human testis cDNA library using sequence specific
primers flanked with restriction enzyme sites at the ends
(see Additional file 1). PCR-generated DNA fragments
were digested with EcoR1 and Nhe1 and cloned into
corresponding sites of pEF2-FLCRF2-12/IFN-γR1 plas-
mid [46] to replace the intracellular domain of IFN-γR1.
The cDNA fragment encoding EGFR extracellular do-
main was amplified by PCR from human EGFR contain-
ing plasmid (Additional file 1). PCR-generated DNA
fragments were digested with Kpn1 and Nhe1 and
cloned into corresponding sites of pEF2- FLCRF2-12
/TAMs plasmid to replace the extracellular domain of
FLCRF2-12. The cloning generated pEF2-EGFR/hTyro3,
pEF2-EGFR/hAxl and pEF2-EGFR/hMertk plasmids,
which contain extracellular domains of human EGFR
and human TAM transmembrane and intracellular do-
mains. The constructs were transfected into 16–9 CHO
cells, a cell line that showed undetectable expression of
any of the three TAMs. Stable single cell derived clonal
populations were generated following G418 selection
and chimeric receptors expression was determined.
Detection of activation of chimeric TAM Receptors
Serum starved, stable EGFR/TAM CHO cells were stimu-
lated with 100 ng/ml hEGF for 5 min and whole cell lysates
were prepared in HNTG buffer (20 mM HEPES, pH 7.5,
150 mM NaCl, 10 % glycerol, 1 % Triton X-100, 1 mM
PMSF, 1 mM Na3VO4, 10 mM Na2MoO4, 1 mM EDTA,
10 mM NaF and 20 μg/mL aprotinin) and processed by im-
munoblotting. EGFR/TAM activation was measured by
pTyro3, pAxl or pMertk signal intensities and normalized
to respective β-Actin protein loading controls.
Detection of surface EGFR expression by flow cytometry
Parental CHO 16–9 cells and stable cell lines expressing
chimeric EGFR/hTYRO3, EGFR/hAXL and EGFR/
hMERTK were seeded in 10-cm dishes and allowed to
attain 80 % confluency. The cells were washed three
times in PBS without calcium and magnesium, incubated
with Accutase® (Innovative Cell Technologies) and col-
lected in FACS stain buffer (PBS with 1 % FBS). The
cells were washed three times in FACS stain buffer,
counted and 1 × 107 cells/mL resuspended in 100 μl
FACS stain buffer. The resuspended cells were incubated
with PE mouse Anti-Human EGF receptor antibody for
30 min on ice according to the manufacture’s protocol.
The cells were then rinsed three times in cold PBS and
the cell pellet resuspended in 0.5-mL of FACS Stain
Buffer. The stained cell samples were analyzed by flow
cytometry (BD FACSCalibur™) and data analyzed using
BD CellQuest Pro software.
Kinome-view profiling
Serum starved, stable EGFR/TAM CHO cells were stim-
ulated with hEGF for 0, 5 and 30 min. The cells were
then lysed in urea buffer (9 M urea, 20 mM Hepes
(pH 8.0), 1 mM sodium orthovanadate, 2.5 mM sodium
pyrophosphate, and 1 mM β-glycerophosphate). 14 μg of
total protein was run in each lane for immunoblotting.
The blots were probed with motif antibodies designed to
provide a Kinome-wide view of cellular phosphorylation.
Immunoblots were developed using a LI-COR Odyssey
NIR (near infrared) imaging system.
Human phospho-kinase array
Human Phospho-kinase arrays were performed accord-
ing to manufacturer’s instructions (R&D Systems).
Briefly, serum starved, stable EGFR/TAM CHO cells
were stimulated with hEGF for 30 min, lysed and 300 μg
of total protein incubated overnight at 4 °C. Membranes
were subsequently washed and subjected to the antibody
array. The membranes were washed again and then
exposed to chemiluminescent reagent and quantification
of pixels was performed by densitometry using Alpha
View software.
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RNA seq, heatmap plot and gene enrichment analysis
(GSEA)
Serum starved, stable EGFR/TAM CHO cells were
stimulated with hEGF for 6 or 24 h. Total cellular RNA
was extracted and analyzed for integrity and samples
with RNA integrity number (RIN) >9.0 were used for
subsequent processing. Total RNA was subjected to two
rounds of poly(A) selection using oligo-d(T)25 magnetic
beads. A single-read (strand specific) cDNA library was
prepared following the Illumina TrueSeq small RNA
protocol for strand-specific RNA-seq with minor modifi-
cations [47]. Briefly, poly(A) + RNA was fragmented in
an alkaline buffer (NaHCO3 at pH 9.3) for 2 min at 94 °C
followed by dephosphorylation with recombinant shrimp
alkaline phosphatase and phosphorylation with T4 poly-
nucleotide kinase. After addition of 3′ adapter (5′ adeny-
lated) and 5′ adapter using truncated T4 RNA ligase II
and T4 RNA ligase I, respectively, RNA was reverse-
transcribed using 3′ adapter-specific primer. cDNA was
then amplified by PCR for 15 cycles with a universal
forward primer and a reverse primer with bar code. The
cDNA libraries were purified using AmpureXP beads and
quantified on an Agilent Bioanalyzer (Additional file 1).
Sequencing was done on NextSeq 500 Illumina with 1x75
configuration. Raw reads were quality trimmed using
Trimmomatic-0.33 with leading and trailing Q score 25,
minimum length 25 bp, and adaptors were removed. The
cleaned reads were mapped to Cricetulus griseus genome,
then aligned reads were counted, both using CLC Genom-
ics Workbench 8.5.1 with CLC Genomics Server 7.0.
The reference genome sequence and annotation files
were downloaded from NCBI (ref_CriGri_1.0_chrUn.fa;
cgr_ref_CriGri_1.0_chrMT.fa; ref_CriGri_1.0_top_level.gff3).
The bioconductor package edgeR_3.8.6 with limma_3.22.7
was used to perform the differential gene expression
analysis, under R environment, R version 3.1.2. Heatmap
was plotted using the log2 transformed CPM expression
values within R heatmap_2 function. Gene sets were cre-
ated specifically for Chinese hamster genome using either
genes from KEGG pathways, or gene selected and anno-
tated based on knowledge. Genes were pre-ranked using
an in-house script, then the GSEA Preranked analysis was
conducted [48].
RT-qPCR
cDNA of Cricetulus griseus mRNA was made using
high capacity cDNA reverse transcription kit using
random primers (Applied Biosystems, Warrington,
UK). Real-time RT-PCR was performed on a Rotor-
gene RG-2000 (Corbett Research, Mortlake NSW,
Australia) by using the Access RT-PCR system (Pro-
mega) according to the manufacturer’s instructions
(Additional file 1).
Adhesion, migration and invasion assays
Real-time cell adhesion, migration and invasion were
determined using Xcelligence system, as previously
described [49]. Briefly, respective cells were serum
starved overnight in medium containing 0.5 % FBS,
counted and resuspended in serum-free medium (SFM).
In the lower chamber of the CIM plate, respective media
containing 10 % FBS was added as chemoattractant. In
the top chamber, 50 μl of SFM was added to all wells for
equilibration step. 100 μl of each cell line suspended in
SFM (40,000 cells/100 μl) ± EGF were added in tripli-
cates in upper chamber wells. Changes in the cell index
(CI) depicting cellular migration, were assessed every
10 min for 24 h and were shown as a change in cell
index versus time. For cell invasion assays, an additional
10 % matrigel plug was added in the upper chamber.
Axl knockout, cell proliferation and in vivo mice studies
Axl knockout cells were prepared by transfecting 4 T1-
luc2-GFP mouse breast cancer cells with two clones of
All-in-one guide RNA (Additional file 1) and flow sorted
for RFP expression. Single cell clones were grown and
screened by immunoblotting and surveyor assay. For cell
proliferation MTT assay, 4 × 103 wild-type (WT) or Axl
KO 4 T1-luc2-GFP cells per well were plated in a 48
well plate and incubated for 24–96 h in pentaplicate.
After the respective time points, MTT (0.5 mg/mL) was
added to each well and incubated for 4 h at 37 °C and
the formazan crystals were then dissolved in 250 μl
DMSO for 30 min at room temperature in the dark. The
absorbance was measured at 490 nm and the cell prolifer-
ation expressed as optical density. For in vivo mice stud-
ies, 5 × 104 WT or Axl KO 4 T1-luc2-GFP cells were
resuspended in matrigel and injected in mammary fat pad
of BALB/C mice (8 mice/group). Tumor volume and body
weights were measured twice and once a week respect-
ively. 5 weeks after the injection, mice were euthanized
and primary tumor and lungs were harvested. Metastatic
index was calculated by counting metastatic nodules in
the lungs. The mouse experiments were done in accord-
ance with guidelines and under approval from IACUC.
Data analysis
Statistical analysis was performed using GraphPad Prism.
Descriptive statistics for quantitative variables were
summarized using mean ± SD or mean ± SEM. Differences
between groups were tested and differences with a P value
of <0.05 were considered statistically significant.
Results
Development of chimeric EGFR-TAM reporter cell lines in
EGFR-negative hamster CHO cells
Previously, we developed TAM-IFNγR1 chimeric re-
porter cell lines to interrogate the activation of TAM
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receptors by their endogenous ligands [25]. These stud-
ies showed that TAMs have distinct ligand-inducible
activation patterns by Gas6 and Pros1, as well as differ-
ential requirement for hyper-activation in the presence
of PS-positive apoptotic cells or PS liposomes. Here, we
have taken a conceptually similar approach and
engineered a new set of chimeric EGFR-TAM gene
products by fusing the extracellular domain of human
EGFR in frame with the trans-membrane and intracellu-
lar domains of each human TAM receptor (Fig. 1 a, b).
TAMs share ~50–55 % identity in their kinase domains,
although there is less conservation in their trans-
membrane regions (20–25 %) and cytoplasmic tails, the
latter of which contains unique autophosphorylation
sites for SH2/PTB domain binding [3] (Fig. 1c). By
expressing EGFR/TAM receptors in EGFR and TAM
negative CHO cells, post-receptor signaling is exquisitely
dependent on EGF stimulation, allowing for normalization
of TAM post-receptor signaling not possible using native
receptors, given native receptors respond differentially to
endogenous ligands.
In Fig. 1d, native CHO cells (parental) were transfected
with EGFR/Tyro3, EGFR/Axl, or EGFR/Mertk expression
plasmids, and after neomycin selection, pooled stable lines
were FACS-sorted with anti-EGFR antibodies that bind
native surface EGFR [50]. Subsequently, geometric mean
intensity gating was used on single cell clones to ensure
equal surface expression of chimeric receptors (Fig. 1d).
After serum starvation for 16 h, parental or EGFR/TAM
CHO cells were stimulated for 5 min with 100 ng/ml EGF,
and detergent lysates prepared and immunoblotted with
native anti-Tyro3 or anti-phosphoTyro3 (Fig. 1e), native
anti-Axl or anti-phosphoAxl (Fig. 1f), or native anti-
Mertk or anti-phosphoMertk antibodies (Fig. 1g). Under
these conditions, EGFR/TAMs maintain minimal, if any,
level of receptor activation in the absence of ligand (EGF),
and demonstrate robust and immediate activation follow-
ing stimulation with EGF (compare upper and lower
panels in Fig. 1, e-g).
Despite the fact that each EGFR/TAM was expressed
at an equal level by sorted populations as measured by
geometric mean-intensities, each TAM displayed differ-
ent morphologies on plastic and fibronectin (FN)
(Fig. 1h, i). In this capacity, EGFR/Axl and EGFR/Tyro3
preferentially showed fusiform-like spindle shaped cells
on both plastic and FN, although EGFR/Axl cells
enhanced this phenotype when cultured on FN. In con-
trast, EGFR/Mertk showed a fusiform-independent
morphology, similar to parental cells, even after TAM
activation on FN (Fig. 1, h-i). Moreover, and consistent
with the fusiform morphology, while all three chimeric
lines collectively induced the EMT marker, N-cadherin,
this effect was most prominent in the EGFR/Axl and
EGFR/Tyro3 cell lines (Fig. 1j).
Furthermore, since TAMs have been intensely interro-
gated as targets of small molecule tyrosine kinase inhibi-
tors, we evaluated whether EGFR/TAM lines could be
used as a screening tool for TAM antagonists. Indeed, as
has been reported for native TAMs [1], EGFR/TAM
chimeric receptors maintain selectivity in their respon-
siveness towards tyrosine kinase inhibitors. For example,
the Axl-specific inhibitor R428 (BGB324) [51] showed
selectivity for Axl (Fig. 1k, l), whereby only EGFR/Axl
cells were inhibited (minimal inhibition of other lines at
up to 1 μM inhibitor concentration). In contrast, when
cells were pretreated with the pan-TAM inhibitor BMS-
777607 [52], all three EGFR/TAMs were equally inhib-
ited in this assay (Fig. 1k, l). These data suggest that
EGFR/TAM lines have utility in drug screening, and by
inference, each TAM kinase domain has distinct
elements for post-receptor activation and substrate-level
phosphorylation, even when the tyrosine kinase
activation is normalized with respect to ligand-induced
dimerization, kinetics of phosphorylation of the activa-
tion loop, and strength of signaling.
Prominent role of Axl in regulation of ligand-induced
cytoskeletal changes and spontaneous metastasis to lung
To translate the contribution of each EGFR/TAM to
specific cell biological outcomes, we examined effect of
EGF stimulation (i.e. TAM activation) on cell adhesion
(Fig. 2a), cell migration (Fig. 2b) and cell invasion
(Fig. 2c) using real-time Xcelligence technology (see
methods). All three EGFR/TAM lines showed enhanced
adhesion on a FN-coated surface, suggesting each TAM
impinged on cytoskeletal reorganization required for
early cell adhesion events. In contrast, when EGFR/
TAM CHO cells were monitored for motility and inva-
sion, each TAM showed differential responsivity,
whereby EGFR/Axl showed greatest effects on chemo-
tactic (migration) activity and invasive activity through a
10 % matrigel membrane. Notably, CHO cells are not
considered invasive (i.e. capable of degrading a 10 %
Matrigel plug). These data suggest that Axl (and to a
lesser extent Tyro3, but not Mertk) activates an intrinsic
post-receptor events associated with invasion, an
important hallmark of metastatic dispersion of primary
tumor cells (Fig. 2b, c).
To extend observations from EGFR/TAM chimeric
receptors, and to validate effects of Axl on motility and
invasion on native full-length receptors, we utilized
CRISPR/Cas9 technology to specifically knockout Axl in
the murine 4 T1 cells (an aggressive triple negative
breast cancer cell line that expresses TAMs, Axl being
more abundant than Tyro3 and Mertk [53]) (Fig. 2d). In
vitro cell proliferation analysis using MTT assay revealed
there were no significant differences in growth charac-
teristics between 4T1 WT and Axl KO at 24, 48 and
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Fig. 1 Characterization of EGFR/TAM chimeric receptors. a Schematic representation of wild-type TAM receptors. The ligands, (Gas6 and Pros1)
serve as bridging molecules to link TAMs on phagocytic cell to externalized PS on apoptotic cells. b Schematic representation of EGFR/TAM
chimeric receptors created by fusing the extracellular domains human EGFR with the trans-membrane and intracellular domains of each TAM
receptor. c The percentage identity between the different domains of TAMs and the different tyrosine-based motifs on TAMs intracellular kinase
domain that can be phosphorylated (the asterisks indicate the autophosphorylation sites). d EGFR expression on stable EGFR/TAM cell lines as
analyzed by flow cytometry. e-g Immunoblots analysis of stable EGFR/Tyro3 (e), EGFR/Axl (f) and EGFR/Mertk (g) CHO cell lines characterizing
receptor expression, and EGF-inducible dimerization and activation of functional proteins verified using pTyro3 (e), pAxl (f), and pMertk
(g) antibodies. h Representative bright-field micrographs of parental and EGFR/TAM CHO cells seeded on fibronectin-coated (upper panels) or
uncoated (lower panels) plastic surface. The Inset shows a representative enlarged single cell. i The cell axial ratio (cell length/width) quantification
data of parental and EGFR/TAM CHO cells seeded on fibronectin-coated or plastic surface. Differences between groups were tested by two-way
ANOVA and Tukey’s multiple comparisons test, *P < 0.05, **P < 0.01, ****P < 0.0001. j Immunoblot analysis of N-Cadherin induction by TAMs.
k Immunoblot analysis showing effects of 200nM R428 and 200nM BMS777607 on TAMs activation. l Densitometry analysis of the immunoblots
showing the percentages of inhibition compared to EGF treatment only. Mean values ± SD are shown (n = 3)
Fig. 2 Effects of Tyro3, Axl and Mertk on Cell adhesion, migration and invasion. a-c Parental and EGFR/TAM CHO cells adhesion (a), migration (b)
and invasion (c), in response to EGF stimulation analyzed by xCELLigence system. d Immunoblot analysis of Axl expression showing CRISPR/Cas9
efficiently disrupts Axl in 4 T1 cell clones 1.2, 1.4, 2.2 and 2.3. 4 T1 Axl knockout clone 2.2 was used in subsequent experiments. e The effect of Axl
knockout on cell growth compared to 4 T1 WT as determined by assessing cell proliferation using an MTT assay for upto 96 h. Mean values ± SD
are shown (n = 5). f BALB/C mice were injected in mammary fat pad with 5 × 104 4 T1 WT or 4 T1 Axl KO clone 2.2 cells, 8 mice per group. On
day 7 after cancer cell implantation, tumor volume measurements began and were performed every 3 days. Mean ± SD is shown, *P < 0.05 by
Student’s t-test. g Quantification of microscopic nodules in the lungs of each group and data presented as the mean ± SE. Statistical analysis was
performed using Student’s t- test. h Representative lung samples showing metastatic nodules in 4 T1 WT vs 4 T1 Axl KO groups. i Total body
weights were not significantly different between the 4 T1 WT and 4 T1 Axl KO groups
Kimani et al. Cell Communication and Signaling  (2016) 14:19 Page 7 of 15
Fig. 3 (See legend on next page.)
Kimani et al. Cell Communication and Signaling  (2016) 14:19 Page 8 of 15
72 h and only a small but significant decrease (<15 %) at
96 h (Fig. 2e). However, when 5 × 104 cells (clone 2.2)
were transplanted into the mammary fat pad of an
immune-competent BALB/C host, AXL KO showed
impaired tumor growth (50 % less tumor volume,
Fig. 2f ), which correlated with less metastasis (50 % less
metastatic burden in the lungs, Fig. 2g, h). Mice injected
with Axl KO and 4T1 WT cells did not differ in average
body weights (Fig. 2i). Collectively, these data suggest
that Axl intrinsically activates an invasive/metastatic
pathway in epithelial cells, consistent with previous re-
ports that demonstrated the essential role of Axl in
EMT transition in breast cancer metastasis [54] and also
in EGFR-targeted drug-resistant tumors [55].
Differential regulation of post-receptor signaling by TAM
receptors
To better understand the mechanisms by which Axl im-
pinges on invasive and metastatic itineraries, and iden-
tify molecular targets involved in post-TAM signaling,
we analyzed detergent lysates from native and EGFR/
TAM stimulated cells with known TAM downstream
substrates, pp90RSK and pAkt, (Fig. 3a), a generalized
pTyr antibody (pY1000) (Fig. 3b), as well as a series of
Phospho-Motif antibodies that include AKT substrates
(RXX(s/t), RXRXX(s/t)) (Fig. 3c), MAPK substrates
(PXsP) (Fig. 3d) and motif antibodies recognizing
substrates for AMPK, PKA/PKC, ATM/ATR, CK, CDK/
tXR), that broadly detect serine, threonine, and tyrosine
phosphorylation events and assess global changes in
protein phosphorylation.
As shown in Fig. 3, whereas all three TAMs induced
rapid tyrosine phosphorylation of RSK, Akt, and Erk,
and clear inductive phosphorylation on both general
tyrosine phosphorylation and substrate level phosphoryl-
ation, they do so with differing kinetics and intensities at
5 and 30 min, indicating that both the robustness and
selectivity of TAM signaling can immediately diverge
following kinase activation (Fig. 3). For example, in the
case for Akt, which is phosphorylated following activa-
tion of all three TAMs, Akt is most robustly phosphory-
lated in the EGFR/Axl stimulated cells, but only
marginally phosphorylated in the EGFR/Tyro3 express-
ing cells. To examine the phosphorylation of Akt more
systematically, which can be phosphorylated on two
sites; threonine 308 (Thr308) in the activation loop by
protein kinase PDK1, and serine 473 (Ser473) in the
C-terminal hydrophobic motif by the mTORC2 complex
[56], we observed Akt to be strongly phosphorylated at
Ser473 by Axl and Mertk, but weakly by Tyro3 and sus-
tained over the 30 min analyzed. Interestingly, whereas
Axl and Mertk strongly phosphorylated Akt at Thr308
albeit with differing kinetics and intensities over the
30 min, Tyro3 failed to show robust phosphorylation of
Akt at Thr308, again revealing differences in Akt phos-
phorylation between TAMs following post-receptor
activation (Fig. 3f ). Similar trends were observed in the
general pTyr blots where both conserved and TAM-
selective phosphorylation events were observed (Fig. 3b,
see arrows), as well as when lysates from the EGFR/
TAM stimulated cells were analyzed by using Akt motif
antibodies, MAPK motif antibodies, and anti-PKA/C
motif antibodies (Fig. 3c-d, summarized in Fig. 3e).
These data indicate that TAM signaling diverges imme-
diately following post-receptor activation.
However, in contrast to the clear up-regulation of
phosphorylation events associated with TAM activation,
in contrast, we found no evidence for post-activation
mediated ubiquitination using a broadly reactive anti-
ubiquitin antibody to access receptor and substrate ubi-
quitination (data not shown), despite earlier reports that
native TAMs (Axl) recruits the E3 ligase Cbl to the
intracellular domain following receptor activation [57].
This suggests that for ligand-inducible TAM ubiquitina-
tion, these post-translational events are likely governed
by extracellular events associated with Gas6/Pros1
induced receptor activation and may involve additional
receptor components.
TAMs differentially affect phospho-proteomics in EGF-
stimulated CHO cells
The aforementioned analysis showing differential phos-
phorylation events for each TAM as well as differences
in the qualitative and quantitative detection of phospho-
proteins prompted us to examine post-receptor signaling
and gene expression profiling using unbiased ap-
proaches. Shown in Fig. 4 are results using a customized
R&D human phospho-kinase array that detects phos-
phorylation of 43 human kinases and their substrates
implicated in signal transduction. Samples were monitored
(See figure on previous page.)
Fig. 3 Phosphoproteomic profiling reveals specific Tyro3, Axl or Mertk dependent changes in protein phosphorylation. Parental and EGFR/TAM
CHO cells were stimulated with EGF for the indicated time points. a Representative PathScan® Multiplex immunoblot analysis of the
phosphorylation patterns of p90RSK and Akt upon TAMs activation for 0, 5 or 30 min. b Immunoblotting analysis of total protein tyrosine
phosphorylation using anti-p-Tyr (pY1000) antibody. c Immunoblotting analysis of Akt substrate phosphorylation using RXX(s/t), RXRXX(s/t) motif
antibody. d Immunoblotting analysis of MAPK substrate phosphorylation using (PXsP) motif antibody. e Summary of the KinomeView profiling
showing the temporal phosphorylation profiles induced by respective TAM activation. f Immunoblotting analysis of time dependent changes in
p-Akt (pT308), p-Akt (pS473) and p-Erk1/2 (pT202/pY204) following 0, 1, 5 10, 15 or 30 min EGF stimulation, with β-actin as the loading control
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in quadruplicate and results normalized as shown in Fig. 4a,
b. All three TAM phosphorylated RSK, Akt, and Erk, albeit
with different kinetics and intensity as noted above (Fig. 3e).
All three TAMs also robustly activated STAT3 (S727),
PLC 1, c-Jun and RSK1/2/3. However, phosphoarrays also
revealed distinct phosphorylation events and patterns, Axl
and Mer kinase domains but not Tyro3 increased the acti-
vation of JNK pan, STAT3 (Y705), STAT5b (Y699),
STAT5α/β (Y694/Y699), PRAS40, p27, p70 S6 Kinase,
WNK-1 and PYK2 by ≥ 1.5 fold. Interestingly, downstream
phosphorylation of p38α, mTOR, AMPKα2, STAT2,
STAT5a (Y694), STAT6, Chk-2, eNOS and GSK-3 α/β was
only significant in Axl kinase domain activation (Fig. 4b).
Notably, Axl exhibited the most robust induction in the
tyrosine phosphorylation of several Src family kinases
(SFKs), including Src, Fyn, Lyn, Fgr, and Lck, as well as
upstream effector of Src, FAK (FAK397), when compared
to Mertk and Tyro3 (Fig. 4c). This is consistent with previ-
ous reports that Axl can employ Src kinases to maximize
cellular invasion in hypoxic tumors [58]. The data is
summarized in Fig. 4d.
Ligand-induced activation of Axl induce genes associated
with metastatic potential
Several of the phosphoproteins detected using motif
antibodies (Fig. 3e) and via phosphoarray interrogation
(Fig. 4a) are known to phosphorylate and activate tran-
scription factors. To profile gene expression patterns
downstream of TAMs, we performed RNAseq analysis
on native and EGFR/TAM lines, following either 6 or
24 h post-EGF stimulation (Fig. 5). The RNAseq data
are available in NCBI’s Sequence Read Archive (SRA)
and are accessible through SRP Study accession number
SRP079404. Following TAM activation, transcriptional
Fig. 4 Differential phosphokinase-array profiles of activated Tyro3, Axl and Mertk. a Representative images of phospho-kinase array experiments
from EGF stimulated parental and EGFR/TAMs total cell lysates. Activation of Tyro3, Axl and Mertk resulted in robust phosphorylation p-ERK1/2
(pT202/pY204, Box1) and p-Akt (pS473, Box2) and whereas only Axl stimulation led to robust phosphorylation of pAkt (pT308, Box3) and pSTAT3
(pS727, Box4). b Semi-quantitative analysis of 2 independent phospho-kinase array experiments showing the fold increase in phosphorylation in
EGF stimulated over respective EGF stimulated parental spots. c Comparison of the fold increase in Src family kinases phosphorylation in Tyro3,
Axl and Mertk, showing Axl activation results in the highest fold increase across all the Src family kinases phosphorylation (see also in a above,
green boxes). d A summary of the signaling pathways downstream of the respective TAM activation
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Fig. 5 Gene-expression profiles influenced by TAMs activation. a Heat map showing differential expression of selected genes in Parental (P), Tyro3
(T), Axl (A) and Mertk (M) upon EGF stimulation for 6 and 24 h. RNA-Seq analysis revealed very distinct transcriptomes in EGFR/TAMs cell lines
upon activation with mostly upregulated (upper panels) or downregulated (lower panels). b Venn diagrams showing the overlap of genes that
significantly changed upon EGF stimulation for 24 h. The numbers represent a list of non-redundant genes with≥ 5-fold, upregulation (upper
panel) or downregulation (lower panel). c, d, e GSEA enrichment plots showing significant enrichment (ES significant at FDR < 25 %) of indicated
gene signatures upregulated in Axl (c), Mertk (d), and Tyro3 (d) cells. f Heat map of the enriched genes involved cell invasion, cell adhesion, ECM
organization and cell survival that displayed fold change ≥2 in gene expression in Parental (P), Tyro3 (T), Axl (A) and Mertk (M) compared to
respective EGF unstimulated controls. The color indicates directionality of change in gene expression (red = increased, white = no change and blue
= decreased). g-i RT–qPCR validation of selected genes differentially upregulated upon 24 h EGF stimulation in EGFR/Axl (g), EGFR/Mertk (h), and
EGFR/Tyro3 (i). The genes are SPP1 in Axl (g), TMEM40 in Mertk (h), and MYH3 in Tyro3 (i). Expression levels are normalized to β-actin expression
levels. Results shown (mean ± SD) are representative data of 3 independent experiments
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analysis of native versus EGFR/TAM cells showed robust
overall changes, with both cohorts of genes up-regulated
(red) and down-regulated (blue) at both 6 and 24 h
(Fig. 5a). While many of the genes showed overlapping
specificity independent of the nature of the TAMs, many
genes were specific to each TAM, which is illustrated in
the Venn diagrams shown in Fig. 5b. Indeed, when we
assessed unique versus overlapping gene sets that were
up-regulated (upper panel) or down-regulated (lower
panel), approximately 30 % non-redundant genes with ≥ 5-
fold, up-regulation (upper panel) or down-regulation
(lower panel) in response to Tyro3, Axl and Mertk activa-
tion (Fig. 5b). Pathway analysis and gene enrichment min-
ing for pathways intrinsic to each TAM (Fig. 5c, d, e)
(using both ingenuity and pathway analysis) showed each
TAM enriched on regulatory pathways that impinged on
cell invasion, cell adhesion, ECM organization, and cell
survival (Fig. 5c, d, e). Interestingly, within these sets, Axl
showed preferential up-regulation of several genes that
impinge on invasion and metastasis, such as MMP10,
MMP12, MMP13, SPP1, and LAMA3 (Fig. 5f). To valid-
ate genes unique to each TAM as determined by the
RNAseq analysis (Fig. 5a), expression of representative
genes that included SPP1 for Axl (Fig. 5g), TMEM40 for
Mertk (Fig. 5h) and Myh3 for Tyro3 (Fig. 5i) was con-
firmed by RT-PCR. Collectively, these data suggest that
TAMs are unique in post-receptor signaling, and reveal a
unique invasive signature for Axl.
Discussion
Clinically, the expression of TAM receptors in primary
tumors has been associated with aggressive clinical
grade, emergence of drug resistance, hallmarks of EMT,
and reduced time to progression and unfavorable sur-
vival outcomes in patients [1, 2]. Moreover, TAMs are
expressed on infiltrating myeloid derived cells and tumor
infiltrating lymphocytes [31] and more recently TAMs
have been recognized as potential inhibitory immune
checkpoint receptors that suppress host tumor immune
responses [57, 59, 60]. At the mechanistic level, the con-
tribution of each TAM in tumor biology is complicated
by the fact that TAMs respond with heterogeneity to
their native ligands, Gas6 and Pros1, having different
affinities and avidities, and different requirements for an-
ionic lipids such as PS on apoptotic cells and liposomes.
Here, we utilized chimeric TAM receptors, whereby the
human EGFR extracellular domain was fused in-frame
to the trans-membrane and intracellular kinase domains
of each TAM receptor in order to establish a normalized
cell based system to study TAM post-receptor signaling
and cell biological outcomes. Interrogating this system,
here we provide evidence that intracellular signaling of
TAMs diverge immediately after receptor dimerization
and activation, enabling TAMs to achieve selectivity in
signaling via the activation of unique post-receptor
signaling events. We also show that Axl-mediated post-
receptor signaling triggers enhanced invasion compared
to Tyro3 and Mertk, offering a partial explanation for
the observed association of Axl expression with
advanced-grade tumors with high metastatic potential.
Using the EGFR/TAM chimeric receptor system,
whereby receptor expression and post-receptor “firing”
is normalized by identical ligand-inducible events, our
results provide a more detailed understanding of how
TAMs achieve intrinsic specificity at the post-receptor
level and conclude that each TAM has unique post-
receptor functions. Evidence to support this idea comes
from several observations from this study that include (i)
TAMs show distinct arrangements of auto-
phosphorylation sites that potentially bind SH2 and PTB-
domain containing proteins (Fig. 1c), (ii) EGFR/TAMs
show differential kinetics and intensities of immediate
post-receptor activation profiles (i.e., pErk1/2, pAkt, and
pRSK2) (Fig. 3a, e, g), (iii) EGFR/TAMs show specificity
(unique) and accentuated phosphor-proteomes using un-
biased phosphoarrays (R&D 43–plex) (Fig. 4), and (iv)
EGFR/TAMs show non-overlapping gene expression pro-
files and signatures (Fig. 5). Together with previous
reports showing that TAMs achieve specificity by their
differential interaction with ligands, the present findings
also suggest that TAM receptors have differential post-
receptor activation that control different biological
outcomes. Further, the notion that TAMs are functionally
distinct is also supported from the pharmacological stud-
ies showing that R428 (BGB324) selectivity inhibits Axl
compared to Tyro3 and Mertk [51]. This observation also
points towards the utility of using EGFR/TAMs for the
screening of pan-TAMs (i.e. BMS777) versus unique
TAMs (i.e. R428) and validation of these small molecule
therapeutics (Fig. 1k, l).
The present study also provides new insight that
defines the oncogenic role of Axl in the malignant phe-
notypes of cancer cells. As noted above, the Axl (Gas6)
axis has been reported in a multitude of human cancers,
and more frequently associated with EMT and metasta-
sis than other TAMs. Indeed, the results of unbiased
proteomic and RNAseq screens not only indicated that
TAMs had unique patterns of post-receptor signaling,
but also identified a putative oncogenic signature for Axl
that impinged on genes associated with invasion such as
MMP10, MMP12, MMP13, and SPP1. EGFR/Axl
activated cells also showed robust activation of Akt on
Thr308 compared to Tyro3 and Mertk, as well as in-
duced more robust and intense phosphorylation of
mTOR, SFKs, and FAK, each of which is involved in
metastatic cell behavior. These oncogenic signatures also
translated into clear morphological and phenotypic
outcomes whereby Axl activates a pro-invasion and pro-
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metastatic switch. When we examined phenotypic out-
comes in the EGFR/TAMs with respect to cell adhesion,
motility, and invasion, the EGFR/Axl-expressing cells
consistently showed enhanced oncogenic parameters,
and promoting invasive properties in CHO cells, a cell
type not reported to have invasive properties. Finally,
and consistent with previous studies using in vivo
models, Axl knockout in the triple-negative 4 T1 breast
cancer model, showed impaired tumor growth which
correlates with decreased lung metastasis.
The observation that Axl preferentially activated
several Src family kinases is consistent with previous ob-
servation showing that Src interacts with Y821 in hAxl,
and in doing so, activates the Src kinase activity leading
the invasive behavior of GBM cells [42]. Axl also prefer-
entially induced tyrosine phosphorylation of FAK on
Y397, a phosphorylation event that creates a docking site
for Src and also linked to the activation of Src family ki-
nases. From these data, we argue that intrinsically, of the
TAMs, Axl is most likely to regulate aggressive cancer
cell hallmarks associated with driver mutations, EMT,
and metastasis. In contrast to Axl, Mertk induces phos-
phorylation of Y867 that controls crosstalk with FAK
and β5 integrin to control efferocytosis (a process of
engulfment of apoptotic cells) [61–63]. This may be an
indication that differential activation of TAMs leads to
distinct functions whereas Src family activation both in
Axl and Mer leads to actin rearrangement, in Axl it is
important for motility and invasion [58] whereas in
Mertk it is important for PS receptor-dependent effero-
cytosis [64, 65], but not motility and invasion.
Conclusion
In summary, we have found that Tyro3, Axl, and Mertk,
despite a high degree of similarity in their kinase
domains, exhibit specificity in post-receptor signaling,
suggesting they can be uniquely exploited and targeted
by anti-TAM therapeutics. These current data, combined
with our previous studies showing selectivity in TAM
activation by Gas6 and Pros1, provide new insight into
the biology of this important family of RTKs.
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